$4.82
0.72% today
Nasdaq, Aug 12, 07:47 pm CET
ISIN
US74587V1070
Symbol
PBYI

Puma Biotechnology, Inc. Stock price

$4.85
+1.46 43.07% 1M
+2.09 75.72% 6M
+1.80 59.02% YTD
+1.39 39.97% 1Y
+1.30 36.62% 3Y
-5.18 51.65% 5Y
-92.16 95.00% 10Y
-8.65 64.07% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+1.16 31.44%
ISIN
US74587V1070
Symbol
PBYI
Industry

Key metrics

Basic
Market capitalization
$244.3m
Enterprise Value
$207.1m
Net debt
positive
Cash
$93.2m
Shares outstanding
49.6m
Valuation (TTM | estimate)
P/E
6.3 | 10.1
P/S
1.0 | 1.1
EV/Sales
0.9 | 0.9
EV/FCF
6.6
P/B
2.5
Financial Health
Equity Ratio
43.2%
Return on Equity
32.9%
ROCE
34.0%
ROIC
47.1%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$232.7m | $222.2m
EBITDA
$48.7m | $40.8m
EBIT
$37.2m | $25.8m
Net Income
$38.1m | $24.0m
Free Cash Flow
$31.2m
Growth (TTM | estimate)
Revenue
2.7% | -3.6%
EBITDA
29.7% | -4.0%
EBIT
43.4% | -16.6%
Net Income
147.5% | -20.9%
Free Cash Flow
-12.2%
Margin (TTM | estimate)
Gross
72.4%
EBITDA
20.9% | 18.4%
EBIT
16.0%
Net
16.4% | 10.8%
Free Cash Flow
13.4%
More
EPS
$0.8
FCF per Share
$0.6
Short interest
6.2%
Employees
172
Rev per Employee
$1.3m
Show more

Is Puma Biotechnology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Puma Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Puma Biotechnology, Inc. forecast:

1x Buy
13%
3x Hold
38%
4x Sell
50%

Analyst Opinions

8 Analysts have issued a Puma Biotechnology, Inc. forecast:

Buy
13%
Hold
38%
Sell
50%

Financial data from Puma Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
233 233
3% 3%
100%
- Direct Costs 64 64
7% 7%
28%
168 168
1% 1%
72%
- Selling and Administrative Expenses 76 76
14% 14%
33%
- Research and Development Expense 55 55
8% 8%
24%
49 49
30% 30%
21%
- Depreciation and Amortization 11 11
1% 1%
5%
EBIT (Operating Income) EBIT 37 37
43% 43%
16%
Net Profit 38 38
148% 148%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Puma Biotechnology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Puma Biotechnology, Inc. Stock News

Neutral
Business Wire
4 days ago
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the issuance of inducement awards to three new hires, as required under Nasdaq Listing Rule 5635(c)(4).
Neutral
The Motley Fool
5 days ago
Puma (PBYI) Q2 Revenue Rises 11%
Neutral
Seeking Alpha
5 days ago
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan H. Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber - Corporate Participant Mariann Ohanesian - Senior Director of Investor Relations Maximo F.
More Puma Biotechnology, Inc. News

Company Profile

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Head office United States
CEO Alan Auerbach
Employees 172
Founded 2010
Website www.pumabiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today